ALK5 INHIBITOR CONJUGATES AND USES THEREOF
The present disclosure relates to targeted drug conjugates comprising ALK5 inhibitors and targeting moieties that direct the ALK5 inhibitors to cells involved in fibrosis and cancer, for example myofibroblasts, activated fibroblasts and transitioning fibroblasts, and their uses, in particular wherein the ALK5 inhibitor is N-methyl-2-(4-(4-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)phenoxy)ethan-1-amine.
1 . A targeted drug conjugate comprising an ALK5 inhibitor operably linked to a targeting moiety that binds to a cell surface molecule expressed on the surface of myofibroblasts, activated fibroblasts, fibroblasts transitioning to myofibroblasts, or a combination thereof, wherein the ALK5 inhibitor is N-methyl-2-(4-(4-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)phenoxy)ethan-1-amine.
2 . The targeted drug conjugate of claim 1 , wherein the ALK5 inhibitor is linked to the targeting moiety via a linker.
3 . The targeted drug conjugate of claim 2 , wherein the linker is a PEG containing linker.
4 . The targeted drug conjugate of any one of claims 1 to 3 , wherein the ALK5 inhibitor is linked to the targeting moiety via a non-cleavable linker or a cleavable linker.
5 . The targeted drug conjugate of claim 4 , wherein the ALK5 inhibitor is linked to the targeting moiety via a non-cleavable linker which is an N-maleimidomethylcyclohexanel-carboxylate, maleimidocaproyl or mercaptoacetamidocaproyl linker.
6 . The targeted drug conjugate of claim 4 , wherein the ALK5 inhibitor is linked to the targeting moiety via a cleavable linker which is a dipeptide linker, a disulfide linker, or a hydrazone linker.
7 . The targeted drug conjugate of claim 6 , wherein the linker is a protease-sensitive valine-citrulline dipeptide linker, a glutathione-sensitive disulfide linker, or an acid-sensitive disulfide linker.
8 . The targeted drug conjugate of claim 7 , wherein the linker is a valine-citrulline dipeptide linker.
9 . The targeted drug conjugate of claim 6 , wherein the linker is a disulfide linker.
10 . The targeted drug conjugate of any one of claims 1 to 9 , wherein the ALK5 inhibitor is conjugated via one or more cysteine residues on the targeting moiety or one or more lysine residues on the targeting moiety, optionally wherein the ALK5 inhibitor is conjugated via a linker.
11 . The targeted drug conjugate of any one of claims 1 to 10 , wherein the average number of ALK5 inhibitor molecules per targeting moiety molecule ranges between 2 and 8.
12 . The targeted drug conjugate of any one of claims 1 to 11 , wherein the targeting moiety comprises an antibody or an antibody fragment.
13 . The targeted drug conjugate of claim 12 , wherein the targeting moiety comprises an antibody.
14 . The targeted drug conjugate of claim 13 , wherein the antibody is a monoclonal antibody.
15 . The targeted drug conjugate of claim 14 , wherein the antibody is human or humanized.
16 . The targeted drug conjugate of claim 12 , wherein the targeting moiety comprises an antibody fragment.
17 . The targeted drug conjugate of claim 16 , wherein the antibody fragment is a Fab, a Fab′, a F(ab′) 2 , a Fv, scFv, a dsFv, or single domain antibody.
18 . The targeted drug conjugate of claim 16 , wherein the antibody fragment is a fragment of a human or humanized antibody.
19 . The targeted drug conjugate of any one of claims 1 to 18 , wherein the cell surface molecule is FAP, PDGFR-β, FGFR1, PPAR-y, FSP1, GFAP, fascin, αvβ6, CD147, CXCR4, αvβ6, AXL, or MERTK.
20 . The targeted drug conjugate of claim 19 , wherein the cell surface molecule is FAP.
21 . A pharmaceutical composition comprising the targeted drug conjugate of any one of claims 1 to 20 and a pharmaceutically acceptable carrier.
22 . The targeted drug conjugate according to any one of claims 1 to 20 or the pharmaceutical composition according to claim 21 for use in a method of treating fibrosis.
23 . The targeted drug conjugate or pharmaceutical composition for use according to claim 22 , wherein the fibrosis is pulmonary fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, skin fibrosis, or esophagus fibrosis.
24 . The targeted drug conjugate or pharmaceutical composition for use according to claim 22 , wherein the fibrosis is idiopathic pulmonary fibrosis (IPF).
25 . The targeted drug conjugate or pharmaceutical composition for use according to any one of claims 22 to 24 , wherein the targeted drug conjugate is administered as monotherapy.
26 . The targeted drug conjugate or pharmaceutical composition for use according to any one of claims 22 to 24 , wherein the targeted drug conjugate is administered as part of a combination therapy regimen.
27 . The targeted drug conjugate or pharmaceutical composition for use according to claim 26 , wherein the combination therapy regimen comprises pirfenidone or nintedanib.
28 . The targeted drug conjugate according to any one of claims 1 to 20 or the pharmaceutical composition according to claim 21 for use in a method of treating systemic sclerosis.
29 . The targeted drug conjugate according to any one of claims 1 to 20 or the pharmaceutical composition according to claim 21 for use in a method of treating cancer.